368 related articles for article (PubMed ID: 25483662)
1. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
Fausther-Bovendo H; Kobinger GP
Hum Vaccin Immunother; 2014; 10(10):2875-84. PubMed ID: 25483662
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.
de Andrade Pereira B; Maduro Bouillet LE; Dorigo NA; Fraefel C; Bruna-Romero O
PLoS One; 2015; 10(12):e0145260. PubMed ID: 26679149
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
5. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.
Coughlan L
Front Immunol; 2020; 11():909. PubMed ID: 32508823
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH
J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.
Sharma A; Tandon M; Ahi YS; Bangari DS; Vemulapalli R; Mittal SK
Gene Ther; 2010 May; 17(5):634-42. PubMed ID: 20164856
[TBL] [Abstract][Full Text] [Related]
9. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
Mastrangeli A; Harvey BG; Yao J; Wolff G; Kovesdi I; Crystal RG; Falck-Pedersen E
Hum Gene Ther; 1996 Jan; 7(1):79-87. PubMed ID: 8825871
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
Zheng X; Rong X; Feng Y; Sun X; Li L; Wang Q; Wang M; Liu W; Li C; Yang Y; Zhou R; Lu J; Feng L; Chen L
Emerg Microbes Infect; 2017 Jun; 6(6):e43. PubMed ID: 28588291
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
[TBL] [Abstract][Full Text] [Related]
12. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.
Smaill F; Jeyanathan M; Smieja M; Medina MF; Thanthrige-Don N; Zganiacz A; Yin C; Heriazon A; Damjanovic D; Puri L; Hamid J; Xie F; Foley R; Bramson J; Gauldie J; Xing Z
Sci Transl Med; 2013 Oct; 5(205):205ra134. PubMed ID: 24089406
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
14. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.
Seregin SS; Amalfitano A
Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714
[TBL] [Abstract][Full Text] [Related]
15. Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon.
Su X; Tian X; Jiang Z; Ma Q; Liu Q; Lu X; Zhou R
PLoS One; 2016; 11(6):e0156984. PubMed ID: 27328032
[TBL] [Abstract][Full Text] [Related]
16. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
17. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
18. Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.
Teigler JE; Kagan JC; Barouch DH
J Virol; 2014 Sep; 88(18):10354-63. PubMed ID: 24991003
[TBL] [Abstract][Full Text] [Related]
19. Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.
Singh S; Vedi S; Samrat SK; Li W; Kumar R; Agrawal B
PLoS One; 2016; 11(1):e0146404. PubMed ID: 26751211
[TBL] [Abstract][Full Text] [Related]
20. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
